Modified RNAi agents
US11406716B2 · kind B2 · utility
3Cited by
23References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 16, 2020 |
| Grant date | Aug 9, 2022 |
| Priority date | — |
| Expiry date | May 12, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/51
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.